After 4 wk of chemotherapy, PET and PSA were in agreement in 86% of cases; in 91% of cases,18F-FDG PET correctly identified progression. not adhere to consensus criteria for clinical trial designs in prostate cancer. Hence, although many promising agents are available for testing, such studies would benefit from closer Continue Reading